“The Tesla and SpaceX CEO sent an email to employees at both companies on Tuesday saying everyone must spend 40 hours per week in the office. ‘If you don’t show up, we will assume you have resigned. The more senior…
HOME > ACADEMIA
ACADEMIA
- Chiba University to Advise Researchers to Retract Diovan Papers
April 28, 2014
- US Journal Corrects COI Disclosure to Clarify Involvement of Shionogi and Eli Lilly Japan in Paper on “Pain in Depression”
April 23, 2014
- JSBMR’s Guidelines Recommend Alendronate, Risedronate as First-Line Therapies for Steroid-Induced Osteoporosis Based on Available Data
April 22, 2014
- Public Hospitals Seeking to Avert Penalty Fee Cuts for Low Price Settlements
April 14, 2014
- JSH Publishes New Hypertension Guidelines
April 3, 2014
- Tolvaptan Reduces Body Weight, Improves Congestive Symptoms; Adverse Reactions Seen in Less than 20% of Patients: Interim Analysis of PMS Data
March 26, 2014
- Edoxaban Subgroup Analysis of East Asian Patients “Consistent” with Global Study Results: Researcher
March 25, 2014
- Revised Treatment Guidelines for HER2-Positive Gastric Cancer Will Recommend Combination Therapy with Trastuzumab
March 25, 2014
- Current Tax Rules for Medical Fees Unreasonable, Litigation an Option: Major Hospital Chain
March 25, 2014
- Experts Disagree over Full-Introduction of GCP at JCS Meeting
March 24, 2014
- NCNP Research Group Confirms Efficacy of Tocilizumab for Neuromyelitis Optica
March 19, 2014
- Japan Hematology Society to Open Probe into SIGN Trial
March 19, 2014
- Lead Author to Revise COI Statement in Article Used to Promote Antidepressant Cymbalta
March 19, 2014
- Trial Investigators Brush Aside Concerns over CASE-J in US Journal
March 18, 2014
- JSH Guidelines to Strongly Recommend Beta Blockers for Patients with Certain Complications
March 18, 2014
- University of Tokyo Admits Patient Information on SIGN Trial Leaked to Novartis
March 17, 2014
- National University Hospitals to Disclose Funding from Autumn, but with Company Names Withheld
March 11, 2014
- JAMS’s Newly Revised COI Management Guidelines Impose Stricter Rules
February 28, 2014
- Japanese Cardiologist Raises Statistical Concerns over CASE-J Study in US Journal
February 28, 2014
- NCNP to Begin Investigator-Initiated Trial of Multiple Sclerosis Treatment
February 28, 2014
ページ
Pharma companies have seen Japan’s new “zero” premium coefficient rule extensively applied to medicines with low cost disclosure ratios since its introduction under the drug pricing reform this April. Of new drugs listed in the past two months, all six…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…